Interferon-alpha or -beta facilitates SARS-CoV-2 pulmonary vascular infection by inducing ACE2
Tóm tắt
Severe viral pneumonia caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is characterized by a hyperinflammatory state typified by elevated circulating pro-inflammatory cytokines, frequently leading to potentially lethal vascular complications including thromboembolism, disseminated intracellular coagulopathy and vasculitis. Though endothelial infection and subsequent endothelial damage have been described in patients with fatal COVID-19, the mechanism by which this occurs remains elusive, particularly given that, under naïve conditions, pulmonary endothelial cells demonstrate minimal cell surface expression of the SARS-CoV-2 binding receptor ACE2. Herein we describe SARS-CoV-2 infection of the pulmonary endothelium in postmortem lung samples from individuals who died of COVID-19, demonstrating both heterogeneous ACE2 expression and endothelial damage. In primary endothelial cell cultures, we show that SARS-CoV-2 infection is dependent on the induction of ACE2 protein expression and that this process is facilitated by type 1 interferon-alpha (IFNα) or -beta(β)—two of the main anti-viral cytokines induced in severe SARS-CoV-2 infection—but not significantly by other cytokines (including interleukin 6 and interferon γ/λ). Our findings suggest that the stereotypical anti-viral interferon response may paradoxically facilitate the propagation of COVID-19 from the respiratory epithelium to the vasculature, raising concerns regarding the use of exogenous IFNα/β in the treatment of patients with COVID-19.
Từ khóa
Tài liệu tham khảo
Adhikari SP et al (2020) Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review. Infect Dis Poverty 9(1):29
Wang Y et al (2020) Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures. J Med Virol. https://doi.org/10.1002/jmv.25748
Poissy J et al (2020) Pulmonary embolism in patients with COVID-19: awareness of an increased prevalence. Circulation 142(2):184–186
Sardu C et al (2020) Hypertension, thrombosis, kidney failure, and diabetes: is COVID-19 an endothelial disease? A comprehensive evaluation of clinical and basic evidence. J Clin Med 9(5):1417
Mao L et al (2020) Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol 77:683
Shi S et al (2020) Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol 5:802
Ackermann M et al (2020) Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med 383(2):120–128
Winkler ES et al (2020) SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function. Nat Immunol 21(11):1327–1335
Zhang H et al (2020) Expression of the SARS-CoV-2 ACE2 receptor in the human airway epithelium. Am J Respir Crit Care Med 202(2):219–229
Hamming I et al (2004) Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol 203(2):631–637
Hoffmann M et al (2020) The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells. bioRxiv 60:1136
Delorey TM et al (2021) COVID-19 tissue atlases reveal SARS-CoV-2 pathology and cellular targets. Nature 595(7865):107–113
Herold T et al (2020) Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19. J Allergy Clin Immunol 146(1):128–136
Del Valle DM et al (2020) An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med 26(10):1636–1643
Ziegler CGK et al (2020) SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. Cell 181(5):1016–1035
Johnson MC et al (2020) Optimized pseudotyping conditions for the SARS-COV-2 spike glycoprotein. J Virol. https://doi.org/10.1128/JVI.01062-20
Onabajo OO et al (2020) Interferons and viruses induce a novel truncated ACE2 isoform and not the full-length SARS-CoV-2 receptor. Nat Genet 52(12):1283–1293
Ng KW et al (2020) Tissue-specific and interferon-inducible expression of nonfunctional ACE2 through endogenous retroelement co-option. Nat Genet 52(12):1294–1302
Blume C et al (2021) A novel ACE2 isoform is expressed in human respiratory epithelia and is upregulated in response to interferons and RNA respiratory virus infection. Nat Genet 53(2):205–214
Huang J et al (2020) SARS-CoV-2 infection of pluripotent stem cell-derived human lung alveolar type 2 cells elicits a rapid epithelial-intrinsic inflammatory response. Cell Stem Cell 27(6):962–973
Davey RA et al (2017) Mechanisms of filovirus entry. Curr Top Microbiol Immunol 411:323–352
Towner JS et al (2005) Generation of eGFP expressing recombinant Zaire ebolavirus for analysis of early pathogenesis events and high-throughput antiviral drug screening. Virology 332(1):20–27
O’Donnell KL, Marzi A (2021) Immunotherapeutics for ebola virus disease: hope on the horizon. Biologics 15:79–86
Dyall J et al (2017) Interferon-beta and interferon-gamma are weak inhibitors of ebola virus in cell-based assays. J Infect Dis 215(9):1416–1420
McCracken IR et al (2021) Lack of evidence of angiotensin-converting enzyme 2 expression and replicative infection by SARS-CoV-2 in human endothelial cells. Circulation 143(8):865–868
Zhao Y et al (2020) Single-cell RNA expression profiling of ACE2, the receptor of SARS-CoV-2. Am J Respir Crit Care Med 202(5):756–759
Ziegler CGK et al (2021) Impaired local intrinsic immunity to SARS-CoV-2 infection in severe COVID-19. Cell 184(18):4713–4733
Zhou Z et al (2020) Heightened innate immune responses in the respiratory tract of COVID-19 patients. Cell Host Microbe 27(6):883–890
Lee JS et al (2020) Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19. Sci Immunol. https://doi.org/10.1126/sciimmunol.abd1554
Hadjadj J et al (2020) Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science 369(6504):718–724
Blanco-Melo D et al (2020) Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell 181(5):1036–1045
Bastard P et al (2021) Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Sci Immunol 6(62):eabl4340
McKechnie JL, Blish CA (2020) The innate immune system: fighting on the front lines or fanning the flames of COVID-19? Cell Host Microbe 27(6):863–869
Nile SH et al (2020) COVID-19: Pathogenesis, cytokine storm and therapeutic potential of interferons. Cytokine Growth Factor Rev 53:66–70
Park A, Iwasaki A (2020) Type I and type III interferons—induction, signaling, evasion, and application to combat COVID-19. Cell Host Microbe 27(6):870–878
Broggi A et al (2020) Type III interferons disrupt the lung epithelial barrier upon viral recognition. Science 369(6504):706–712
Wang N et al (2020) Retrospective multicenter cohort study shows early interferon therapy is associated with favorable clinical responses in COVID-19 patients. Cell Host Microbe 28(3):455–464
Sposito B et al (2021) The interferon landscape along the respiratory tract impacts the severity of COVID-19. Cell 184(19):4953–4968
Eppihimer MJ et al (2002) Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells. Microcirculation 9(2):133–145
Li S et al (2020) SARS-CoV-2 triggers inflammatory responses and cell death through caspase-8 activation. Signal Transduct Target Ther 5(1):235
Varga Z et al (2020) Endothelial cell infection and endotheliitis in COVID-19. Lancet 395(10234):1417–1418